Related Experiment Videos
The thyromimetic T-0681 protects from atherosclerosis
Ivan Tancevski1, Andreas Wehinger, Egon Demetz
1Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria. ivan.tancevski@i-med.ac.at
Journal of Lipid Research
|December 25, 2008
Summary
Liver-selective thyromimetic T-0681 significantly reduces plasma cholesterol and triglycerides in rabbits. This compound also markedly inhibits atherosclerosis development, suggesting therapeutic potential for human cardiovascular disease.
Area of Science:
- Pharmacology
- Cardiovascular Science
- Metabolic Research
Background:
- Hyperlipidemia and atherosclerosis are major cardiovascular risks.
- Liver-selective thyromimetics offer a targeted approach to metabolic regulation.
- Understanding T-0681's effects on lipoprotein metabolism is crucial.
Purpose of the Study:
- To investigate the impact of T-0681 on lipoprotein metabolism.
- To assess T-0681's efficacy in preventing atherosclerosis development.
- To evaluate T-0681 as a potential therapeutic agent.
Main Methods:
- Studies conducted in hyperlipidemic New Zealand White rabbits.
- Analysis of hepatic lipoprotein receptor expression (LDL receptor, SR-BI).
- Measurement of plasma lipid levels (cholesterol, triglycerides) and atherosclerosis progression.
Main Results:
- T-0681 increased hepatic LDL receptor and scavenger receptor class B, type I expression.
- Plasma cholesterol reduced by 60% and triglycerides by over 70%.
- Atherosclerosis development was reduced by 80% in T-0681 treated rabbits.
Conclusions:
- T-0681 effectively modulates lipoprotein metabolism.
- Liver-selective thyromimetics demonstrate significant anti-atherosclerotic effects.
- T-0681 shows promise as a therapeutic for atherosclerosis.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:20Synthesis and Regulation of Thyroid Hormones
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:25Hyperthyroidism I: Introduction
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
01:23Hypothyroidism II: Pathophysiology
Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...